Clinical Trial Update: To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trials evaluating nemolizumab for chronic kidney disease-associated pruritus have completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Chronic Kidney Disease Associated Moderate to Severe Pruritus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-02-20